Lack of influence of pantoprazole on the disposition kinetics of theophylline in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue SUPPL. 1, 1996, Pages

  Schulz, H U ^a   Hartmann, M ^b   Steinijans, V W ^b   Huber, R ^b   Luhrmann B ^a   Bliesath, H ^b   Wurst, W ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

BY1023 SKandF96022; Interaction; Pantoprazole; Theophylline

Indexed keywords

BRONCHODILATING AGENT; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INTERACTION; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; THEOPHYLLINE BLOOD LEVEL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; BENZIMIDAZOLES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OMEPRAZOLE; SULFOXIDES; THEOPHYLLINE;

EID: 0030003979     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Campbell ME, Grant DM, Inaba T, Kalow W 1987 Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon - inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15: 237-249
2. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
3. Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA 1983 Bayesian approach to bioequivalence assessment: An example. J Pharm Sci 72: 1178-1181
4. Hauschke D, Steinijans VW, Diletti E 1990 A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 72-78
5. +-ATPase inhibitor BY1023/SK&F96022 and its sulphone metabolite in serum or plasma by direct injection and fully automated precolumn sample cleanup. J Chromatogr 529: 389-401
6. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U, Gönne S, Parsons ME 1990 BY1023/SKF96022 INN pantoprazole, a novel gastric proton pump inhibitor potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 254: 129-135
7. Lohmann SM, Miech RP 1976 Theophylline metabolism by the rat liver microsomal system. J Pharmacol Exp Ther 196: 213-225
8. Ogilvie RI 1978 Clinical pharmacokinetics of theophylline. Clin Pharmakokinet 3: 267-293
9. Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, Birkett DJ 1988 Characterization of theophylline metabolism by human liver microsomes. Biochem Pharmacol 37: 1651-1659
10. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680
11. Schulz H-U, Steinijans VW, Gabel H 1984 Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing. Int J Clin Pharmacol Ther Toxicol 22: 621-625
12. +-ATPase inhibitor BY1023/SK&F96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239-245
13. +-ATPase inhibitor pantoprazole (BY1023/SKF96022) in healthy volunteers. Z Gastroenterologie 9: 443-447
14. +-ATPase inhibitor pantoprazole (BY1023/ SK&F96022). 9th World Congress of Gastroenterology, Sydney 1990
15. Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann M, Wurst W 1990d Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 373-379
16. +-ATPase inhibitor pantoprazole (BY 1023/ SK&F96022) interacts less with cytochrome P-450 than omeprazole and lansoprazole. Biochem Pharmacol 42: 347-355
17. Steinijans VW, Hauschke D 1990 Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 105-110
18. Steinijans VW, Hartmann M, Huber R, Radtke HW 1991 Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
19. Upton RA, Thiercelin JF, Guentert TW, Wallace SM, Powell JR, Sansom L, Riegelman S 1982 Intraindividual variability in theophylline pharmacokinetics: Statistical verification in 39 of 60 healthy young adults. J Pharmacokinet Biopharm 10: 123-134